ANIP at a glance
ANI PHARMACEUTICALS INC (ANIP, SEC CIK 1023024) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on August 24, 2026 and Form 4 insider filings as recently as September 30, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ANI PHARMACEUTICALS INC (ANIP) reported revenue of $883.4 million (up 43.8% from FY2024) and net income of $78.3 million. Diluted EPS was $3.32.
- As of June 30, 2026, 34 institutional investment managers tracked by SignalX reported holding ANI PHARMACEUTICALS INC (ANIP) shares worth $735.1 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by CAREY STEPHEN P. on September 29, 2026 of 2,850 shares at $73.00 per share.
- In the last 90 days, ANIP insiders reported 0 open-market purchases ($0) and 10 open-market sales ($1.9M) on Form 4, a net sale of $1.9M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $883.4M
- +43.8% vs prior year
- Insiders · 90 days
- 0 buys · 10 sells
- Net −$1.9M
- 13F holders
- 34 funds
- $735.1M · +2 vs prior quarter
- Latest 8-K
- Aug 24, 2026
- Item 5.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: developing, manufacturing, commercializing therapeutics via Rare Disease, Generics, and Brands segments
- Acquired Alimera Sciences on September 16, 2024, adding ILUVIEN® and YUTIQ® products
- Strategic expansion into ophthalmic specialty products through acquisition
- Acquisition introduces new product lines, diversifying portfolio beyond prior scope
Risk Factors
- Regulatory/legal risk: Compliance with Medicaid Drug Rebate Program risks material penalties due to increased rebate accruals from branded and authorized generic products
- Geopolitical/macro risk: 17% of raw materials/API from one domestic supplier in 2025; supply disruption risk from FDA inspections and trade or geopolitical tensions
- Operational/supply chain risk: Reliance on single-source third-party contract manufacturers for Cortrophin Gel and ILUVIEN, risking commercialization delays if noncompliant or unavailable
- Competitive risk: Dependence on Cortrophin Gel, competing with major pharma companies and generics that may have fewer side effects and higher physician acceptance
- Financial/structural risk: 2024 Credit Agreement contains restrictive financial covenants, with potential for accelerated debt repayment and termination if breached
Management Discussion & Analysis
- Total revenue details not provided for FY 2024; Alimera acquisition adds ILUVIEN® and YUTIQ® franchises
- No segment-specific revenue or profit data disclosed
- Sale of Oakville facility for $14.2 million completed in March 2024; no other cash flow or capital allocation details given
- Management highlights growth via ILUVIEN label expansion and Alimera acquisition; no formal guidance or risk outlook stated
AI summary of the ANIP 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No risk factors provided in the submitted excerpt
- Executive Rule 10b5-1 plans for sales of up to 39,040 shares beginning August–September 2026
- Employee tax-withholding share transfers totaled 10,425 shares at $78.00 average
AI summary of the ANIP 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Henry Gosebruch appointed director through 2027 annual meeting, adding M&A, strategy, and biopharma leadership experience
- Initial restricted stock award valued at $525,000, vesting in three equal annual installments
Item 7.01: Regulation FD Disclosure
- Updated investor presentation published August 7, 2026 under Regulation FD
- Presentation may guide future investor and analyst meetings
Item 2.02: Results of Operations and Financial Condition
- Filing contains only the signature page, not substantive Item 2.02 operating results
- CFO Stephen P. Carey signed the report on August 7, 2026
Item 7.01: Regulation FD Disclosure
- Filing contains only the required signature block dated May 13, 2026
- No substantive Regulation FD disclosure or investor-impacting information provided
AI summaries of ANIP 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ANIP
Don't miss the next ANIP filing
- Alerts as it files. A push when ANIP files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ANIP, by share count.
- Ask anything. An AI agent that reads every ANIP filing and answers with sources.
ANIP alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| CAREY STEPHEN P. | Sell | Sep 29, 2026 | 2,850 | $73.00 |
| Lalwani Nikhil | Sell | Sep 15, 2026 | 5,400 | $71.00 |
| Cook Meredith | Sell | Sep 14, 2026 | 500 | $70.79 |
| Thoma Jeanne | Sell | Sep 11, 2026 | 1,000 | $71.53 |
| CAREY STEPHEN P. | Sell | Aug 31, 2026 | 2,850 | $72.80 |
| Lalwani Nikhil | Sell | Aug 25, 2026 | 5,400 | $74.30 |
| Gosebruch Henry O | A | Aug 19, 2026 | 6,662 | - |
| Cook Meredith | Sell | Aug 13, 2026 | 500 | $75.48 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $614.4M | $883.4M |
| Operating Income | - | $584K | $111.1M |
| Net Income | $18.8M | -$18.5M | $78.3M |
| Op. Margin | - | 0.1% | 12.6% |
| Net Margin | - | -3.0% | 8.9% |
| Balance Sheet | |||
| Total Assets | $904.4M | $1.3B | $1.4B |
| Equity | - | $403.7M | $540.7M |
| ROE | - | -4.6% | 14.5% |
| Per Share | |||
| EPS | $0.85 | $-1.04 | $3.32 |
| Cash Flow | |||
| Operating CF | - | $64.0M | $185.2M |
| CapEx | $8.9M | $16.2M | $13.8M |
Source: XBRL data in ANI PHARMACEUTICALS INC (ANIP)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ANIP share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 34 | $735.1M |
| Q1 2026 | 32 | $663.3M |
| Q4 2025 | 31 | $688.2M |
| Q3 2025 | 30 | $772.5M |
| Q2 2025 | 29 | $590.4M |
| Q1 2025 | 27 | $497.3M |
| Q4 2024 | 21 | $317.9M |
| Q3 2024 | 21 | $222.1M |
- BlackRock+211.2K (+8%)
- Dimensional Fund Advisors+92.3K (+17%)
- State Street Corp+60.1K (+8%)
- Raymond James Financial+50.6K (+63%)
- Bank of America Corp+32.5K (+22%)
- Renaissance Technologies LLC−122.4K (-66%)
- Millennium Management−84.8K (-14%)
- D.E. Shaw & Co−38.7K (-18%)
- Goldman Sachs Group−37.5K (-17%)
- Two Sigma Investments−32.6K (-34%)
- HANCOCK WHITNEY CORP+3.5K
- Truist Financial+3.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 225 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ANIP filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 30, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Aug 27, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 8-K | Aug 24, 2026 | - | Analysis | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 10-Q | Aug 7, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 7, 2026 | - | Analysis | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 21, 2026 | - | - | - |
| 4 | Jul 14, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 8-K | May 13, 2026 | - | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ANIP SEC filings: frequently asked questions
Are ANIP insiders buying or selling?
In the last 90 days, ANI PHARMACEUTICALS INC (ANIP) officers, directors and 10% owners reported no open-market purchases and 10 open-market sales worth $1.9 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ANIP stock?
As of June 30, 2026, the largest ANI PHARMACEUTICALS INC (ANIP) holders among the 13F filers tracked by SignalX were BlackRock ($244.9 million), Vanguard Capital Management LLC ($69.4 million), State Street Corp ($68.9 million), Dimensional Fund Advisors ($51.6 million), Millennium Management ($42.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ANIP's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ANI PHARMACEUTICALS INC (ANIP) reported revenue of $883.4 million (up 43.8% from FY2024) and net income of $78.3 million. Diluted EPS was $3.32. The figures come from the XBRL data in the 10-K.
What are the main risks in ANIP's latest 10-K?
In the 10-K filed February 27, 2026, ANI PHARMACEUTICALS INC (ANIP) flagged: Regulatory/legal risk: Compliance with Medicaid Drug Rebate Program risks material penalties due to increased rebate accruals from branded and authorized generic products. Geopolitical/macro risk: 17% of raw materials/API from one domestic supplier in 2025; supply disruption risk from FDA inspections and trade or geopolitical tensions. (AI summary of the Risk Factors section.)
What did ANIP report in its latest 8-K?
ANI PHARMACEUTICALS INC (ANIP) filed an 8-K on August 24, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Henry Gosebruch appointed director through 2027 annual meeting, adding M&A, strategy, and biopharma leadership experience.
What are the latest ANIP SEC filings?
ANI PHARMACEUTICALS INC (ANIP) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on August 24, 2026 and a Form 4 insider filing on September 30, 2026.
What is ANIP's SEC CIK number?
ANI PHARMACEUTICALS INC (ANIP)'s SEC Central Index Key (CIK) is 1023024. EDGAR lists every ANIP filing under that number.
Ask anything about ANIP
The research agent reads ANIP's filings, financials, insider trades and 13F holders, then answers with sources.